InvestorsHub Logo
icon url

BonelessCat

02/26/17 9:57 AM

#173393 RE: xoc #173383

Not really. I was referring to the parabolic rise that shot the price in several steps from a buck and change to over $100 in a very short period.
icon url

Waverunner1

02/26/17 6:17 PM

#173418 RE: xoc #173383

Actually, the $21B figure was only for half interest in the drug. Implied value was $42B.


Even after the past two years of deals, AbbVie's ($ABBV) decision to pay $21 billion for Pharmacyclics, bagging half interest in the blockbuster cancer drug Imbruvica, managed to get jaws to drop among even the most jaded biotech analysts.



http://www.fiercebiotech.com/biotech/surprised-stunned-and-supportive-analysts-assess-abbvie-s-21b-pharmacyclics-deal


PCYC sale was for 21 billion, not 11 billion. Does that change your numbers for CTIX?